Phase 3 Trial Shows Lonapegsomatropin Is Superior to Somatropin in Treatment-Naïve Children with Growth Hormone Deficiency

October 18, 2021

The investigational long-acting, once-weekly prodrug lonapegsomatropin (TransCon hGH) may be more beneficial to treatment-naïve pediatric patients with growth hormone deficiency (GHD) than daily somatropin of equivalent weekly dose, according to a paper recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Aimee D. Shu, MD, of Ascendis Pharma (who funded the […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Growth Issues Pediatric Health

←Handling Health Disparities One Patient at a Time

In Memoriam: Arnold M. Moses, 1928-2021→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today